STOCK TITAN
  1. Home
  2. Sec-filings
  3. BSX
  4. [Form 4] BOSTON SCIENTIFIC CORP Insider Trading Activity

Boston Scientific (NYSE: BSX) director granted deferred stock units

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Pegus Cheryl reported acquisition or exercise transactions in this Form 4 filing.

Boston Scientific director Cheryl Pegus received two compensation grants of deferred stock units, not open-market purchases or sales. On May 7, 2026, she was awarded 3,800 deferred stock units representing an annual equity award valued at $215,000, based on the closing share price that day. She also received 1,281 deferred stock units granted in lieu of 50% of her yearly cash and committee chair retainers, reflecting a value of $72,500 divided by the same closing price. Each deferred stock unit represents a commitment to issue one share of Boston Scientific common stock, vesting in full at the next annual stockholders’ meeting, with shares delivered after she leaves Board service under the Non-Employee Director Deferred Compensation Plan. Following these awards, she directly holds 10,998 deferred stock units.

Positive

  • None.

Negative

  • None.
Insider Pegus Cheryl
Role null
Type Security Shares Price Value
Grant/Award Deferred Stock Units 3,800 $0.00 --
Grant/Award Deferred Stock Units 1,281 $0.00 --
Holdings After Transaction: Deferred Stock Units — 9,717 shares (Direct, null)
Footnotes (1)
  1. Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant. Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Deferred stock units were granted in lieu of 50% yearly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $72,500 (representing 50% of the amount of the non-employee director compensation program's cash retainer having a value of $125,000 and committee chair retainer having a value of $20,000) divided by the closing price of the common stock on the date of grant.
Annual equity DSU grant 3,800 deferred stock units Annual equity award on May 7, 2026
Equity grant value $215,000 Value of 3,800 deferred stock units based on closing price
DSUs in lieu of cash 1,281 deferred stock units Granted instead of 50% yearly cash and chair retainers
Cash-for-DSU value $72,500 Value of DSUs replacing 50% of cash compensation
Post-award DSU holdings 10,998 deferred stock units Direct holdings following reported transactions
Cash retainer reference $125,000 cash retainer; $20,000 chair retainer Inputs used to compute the $72,500 DSU grant value
Deferred Stock Units financial
"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."
Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.
annual equity award financial
"Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders."
Non-Employee Director Deferred Compensation Plan financial
"in accordance with the Company's Non-Employee Director Deferred Compensation Plan."
cash retainer financial
"representing 50% of the amount of the non-employee director compensation program's cash retainer having a value of $125,000"
committee chair retainer financial
"and committee chair retainer having a value of $20,000"
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Pegus Cheryl
(Last)(First)(Middle)
300 BOSTON SCIENTIFIC WAY
(Street)
MARLBOROUGH MASSACHUSETTS 01752-1234
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Deferred Stock Units(1)05/07/2026A3,800(2) (3) (3)Common Stock3,800$0.00009,717D
Deferred Stock Units(1)05/07/2026A1,281(4) (4) (4)Common Stock1,281$0.000010,998D
Explanation of Responses:
1. Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
2. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.
3. Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan.
4. Deferred stock units were granted in lieu of 50% yearly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $72,500 (representing 50% of the amount of the non-employee director compensation program's cash retainer having a value of $125,000 and committee chair retainer having a value of $20,000) divided by the closing price of the common stock on the date of grant.
/s/ Susan Thompson, Attorney-in-Fact05/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Boston Scientific (BSX) report for Cheryl Pegus?

Boston Scientific director Cheryl Pegus received two grants of deferred stock units as compensation, not open-market trades. She was awarded 3,800 units as an annual equity grant and 1,281 units in lieu of 50% of her yearly cash and committee chair retainers.

How many deferred stock units did Cheryl Pegus receive in the latest BSX Form 4?

Cheryl Pegus received a total of 5,081 deferred stock units at Boston Scientific. This includes 3,800 units as an annual equity award and 1,281 units granted instead of part of her cash compensation, all based on the closing stock price on May 7, 2026.

What is the dollar value of Cheryl Pegus’ new deferred stock unit awards at BSX?

The new deferred stock unit awards to Cheryl Pegus reflect values of $215,000 and $72,500. The 3,800-unit equity grant corresponds to $215,000, and the 1,281-unit grant in lieu of cash compensation corresponds to $72,500, each divided by Boston Scientific’s closing stock price on grant date.

When do Cheryl Pegus’ Boston Scientific deferred stock units vest and get paid?

Both Boston Scientific deferred stock unit grants to Cheryl Pegus vest in full at the next annual meeting of stockholders. The underlying shares of common stock will then be issued only after her separation from Board service, under the company’s Non-Employee Director Deferred Compensation Plan.

How many deferred stock units does Cheryl Pegus hold after these BSX awards?

After the reported awards, Cheryl Pegus directly holds 10,998 deferred stock units at Boston Scientific. Each deferred stock unit represents a commitment by the company to issue one share of its common stock, subject to vesting and later delivery following her departure from the Board.